As Vitrakvi (larotrectinib) becomes the second drug to get FDA approval for a site-agnostic indication, physicians will have yet another reason to order sequencing, said David Hyman, chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center and the principal investigator for a larotrectinib clinical trial that led to the approval.
The NCI Human Tumor Atlas Network (HTAN) has published a cluster of papers intended to advance the framework of spatial omics, the science of profiling morphological and molecular features of human cancers in two and three dimensions.
